Sera Prognostics, Inc., a women’s health company, discovers, develops, and commercializes blood-based biomarker tests, and predictive analytic products and services in the United States. The company develops the PreTRM test, a non-invasive blood test given to a pregnant woman, carrying a single fetus, during weeks 18 through 20 of gestation. It is also involved in the development of a pipeline of novel blood-based biomarker tests and predictive analytic products and services for pregnancy related conditions, such as time-to-birth, predictive analytics product, pregnancy risk prediction panel, preeclampsia, and fetal growth restriction. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
Name | Title | Since | Age |
|---|---|---|---|
| Kim Puloma Kamdar | Independent Chairman | 2023 | 59 |
| Zhenya Lindgardt | President, CEO & Director | 2023 | 52 |
| Gregory C. Critchfield | Executive Director | 2023 | 73 |
| Sandra A. J. Lawrence | Independent Director | 2021 | 68 |
| Jane F. Barlow | Independent Director | 2022 | 65 |
| Robert H. Getzenberg | Member of Scientific Advisory Board | - | - |
| Amos E. Madanes | Member of Scientific Advisory Board | - | - |
| C. Matthew Peterson | Member of Scientific Advisory Board | - | - |
| D. Ware Branch | Member of Scientific Advisory Board | - | - |
| Robert M. Silver | Member of Scientific Advisory Board | - | - |
| Joshua S. Phillips | Independent Director | 2011 | 59 |
| David G. Grenache | Member of Scientific Advisory Board | - | - |
| Mansoor Raza Mirza | Independent Director | 2014 | 65 |
| Mark Christopher Capone | Independent Director | 2026 | 64 |